NCT00570882View on ClinicalTrials.gov

Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

Sunitinib 2/1

Sunitinib 50 mg PO 2 weeks followed by 1 week rest

DRUG

Sunitinib 4/2

Sunitinib 50 mg PO 4 weeks followed by 2 week rest

Trial Locations (3)

Unknown

Daegu Catholic University Hospital, Daegu

Yeungnam University Medical Center, Daegu

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER